Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12–49. https://doi.org/10.3322/caac.21820

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Zhu Y, Mo M, Wei Y et al (2021) Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 18:282–301. https://doi.org/10.1038/s41585-021-00442-8

Article  CAS  PubMed  Google Scholar 

Feng RM, Zong YN, Cao SM et al (2019) Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun (Lond) 39:22. https://doi.org/10.1186/s40880-019-0368-6

Article  PubMed  Google Scholar 

Satapathy S, Yadav MP, Ballal S et al (2024) [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging 51:2495–2503. https://doi.org/10.1007/s00259-024-06677-y

Article  CAS  PubMed  Google Scholar 

Sommer U, Siciliano T, Ebersbach C et al (2022) Impact of androgen receptor activity on prostate-specific membrane antigen expression in prostate cancer cells. Int J Mol Sci 23:1046. https://doi.org/10.3390/ijms23031046

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekhoacha M, Riet K, Motloung P et al (2022) Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules 27:5730. https://doi.org/10.3390/molecules27175730

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferdinandus J, Violet J, Sandhu S et al (2018) Prostate-specific membrane antigen theranostics: therapy with lutetium-177. Curr Opin Uro 28:197–204. https://doi.org/10.1097/MOU.0000000000000486

Article  Google Scholar 

Zamboglou C, Strouthos I, Sahlmann J et al (2022) Metastasis-free survival and patterns of distant metastatic disease after prostate-specific membrane antigen positron emission tomography (PSMA-PET)-guided salvage radiation therapy in recurrent or persistent prostate cancer after prostatectomy. Int J Radiat Oncol Biol Phys 113:1015–1024. https://doi.org/10.1016/j.ijrobp.2022.04.048

Article  PubMed  Google Scholar 

Roberts MJ, Maurer T, Perera M et al (2022) Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol 20:23–47. https://doi.org/10.1038/s41585-022-00670-6

Article  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN et al (2021) Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091–1103. https://doi.org/10.1056/NEJMoa2107322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duan X, Cao Z, Zhu H et al (2022) 68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent. Eur J Nucl Med Mol Imaging 49:1030–1040. https://doi.org/10.1007/s00259-021-05486-x

Article  CAS  PubMed  Google Scholar 

Li Y, Duan X, Xu H et al (2022) Optimization of ODAP-Urea-based dual-modality PSMA targeting probes for sequential PET-CT and optical imaging. Bioorg Med Chem 66:116810. https://doi.org/10.1016/j.bmc.2022.116810

Article  CAS  PubMed  Google Scholar 

Duan X, Liu F, Kwon H et al (2020) (S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic Acid as A Novel PSMA targeting scaffold for prostate cancer imaging. J Med Chem 63:3563–3576. https://doi.org/10.1021/acs.jmedchem.9b02031

Article  CAS  PubMed  Google Scholar 

Violet J, Jackson P, Ferdinandus J et al (2019) Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 60:517–523. https://doi.org/10.2967/jnumed.118.219352

Article  CAS  PubMed  Google Scholar 

Schuchardt C, Zhang J, Kulkarni HR et al (2022) Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med 63:1199–1207. https://doi.org/10.2967/jnumed.121.262713

Article  CAS  PubMed  PubMed Central  Google Scholar 

Satchell S (2013) The role of the glomerular endothelium in albumin handling. Nat Rev Nephrol 9:717–725. https://doi.org/10.1038/nrneph.2013.197

Article  CAS  PubMed  Google Scholar 

Ballermann BJ, Nyström J, Haraldsson B (2021) The glomerular endothelium restricts albumin filtration. Front Med (Lausanne) 8:766689. https://doi.org/10.3389/fmed.2021.766689

Article  PubMed  Google Scholar 

Tayyab S, Feroz SR (2021) Serum albumin: clinical significance of drug binding and development as drug delivery vehicle. Adv Protein Chem Struct Biol 123:193–218. https://doi.org/10.1016/bs.apcsb.2020.08.003

Article  CAS  PubMed  Google Scholar 

Yang X, Mease RC, Pullambhatla M et al (2016) [18F]Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA). J Med Chem 59:206–218. https://doi.org/10.1021/acs.jmedchem.5b01268

Article  CAS  PubMed  Google Scholar 

Bergazin TA-O, Tielker NA-O, Zhang YA-OX et al (2021) Evaluation of log P, pKa, and log D predictions from the SAMPL7 blind challenge. J Comput Aided Mol Des 3:771–802. https://doi.org/10.1007/s10822-021-00397-3

Article  CAS  Google Scholar 

Staniszewska M, Fragoso Costa P, Eiber M et al (2021) Enzalutamide enhances PSMA expression of psma-low prostate cancer. Int J Mol Sci 22:7431. https://doi.org/10.3390/ijms22147431

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M-H, Lo S-N, Chen M-W et al (2021) Molecular imaging for radiolabeling a PSMA-targeted long circulating peptide as a theranostic agent in mice bearing a human prostate tumor. J Med Biol Eng 41:360–368. https://doi.org/10.1007/s40846-021-00611-5

Article  Google Scholar 

Deberle LM, Benešová M, Umbricht CA et al (2020) Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics 10:1678–1693. https://doi.org/10.7150/thno.40482

Article  CAS  PubMed  PubMed Central  Google Scholar 

Echigo H, Mishiro K, Munekane M et al (2024) Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (211 At). Eur J Nucl Med Mol Imaging 51:412–421. https://doi.org/10.1007/s00259-023-06457-0

Iikuni S, Ohara T, Watanabe H et al (2022) Structure-activity relationships and pharmacokinetics of 111In-labeled glucagon-like Peptide-1 receptor-targeting exendin-4 derivatives conjugated with albumin binder moieties. Mol Pharm 19:2832–2839. https://doi.org/10.1021/acs.molpharmaceut.2c00201

Article  CAS  PubMed  Google Scholar 

Benesova M, Schafer M, Bauder-Wust U et al (2015) Preclinical evaluation of a tailor-made DOTA-Conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56:914–920. https://doi.org/10.2967/jnumed.114.147413

Article  CAS  PubMed  Google Scholar 

Meyer C, Prasad V, Stuparu A et al (2022) Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 12(1):65. https://doi.org/10.1186/s13550-022-00935-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chopra S, Mathur Y, Roesch F, Moon ES, Rana N, Irrinki S, Walia R, Duseja A, Singh H, Kumar R, Shukla J (2024) 68Ga-DOTA SA FAPi as a versatile diagnostic probe for various epithelial malignancies: a head-to-head comparison with 18F-FDG. Academ Radiol 31(6):2521–35. https://doi.org/10.1016/j.acra.2023.12.002

Wen X, Xu P, Zeng X et al (2023) Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging 50:2846–2860. https://doi.org/10.1007/s00259-023-06229-w